Lipocine Inc.’s SEC filings document the regulatory record for a clinical-stage biopharmaceutical company focused on oral drug-delivery products. Recent 8-K filings furnish financial results, operational updates, corporate presentations and clinical disclosures for LPCN 1154 in postpartum depression, along with information on TLANDO licensing and royalty-related business activity.
The company’s filings also cover governance and capital-structure matters. Proxy materials describe annual meeting voting matters and board oversight, while current reports document board composition changes and common-stock offering documentation connected to an equity distribution arrangement. These filings frame Lipocine’s pipeline development, commercialization agreements, financing tools, risk disclosures and public-company governance.
Lipocine Inc., a clinical‑stage biopharma company focused on oral hormone and CNS therapies, reported Q2 2026 revenue of $190,099, all from TLANDO royalties, and a net loss of $2.6 million (H1 2026 loss $6.3 million on $309,496 revenue). Operating expenses increased year to date versus 2025, mainly from higher research and development spending.
Cash and cash equivalents were $4.98 million with $18.29 million in marketable securities at June 30, 2026. After raising $13.5 million net through at‑the‑market share sales, management expects existing capital to fund operations through at least August 4, 2027, while still anticipating additional financing over the longer term. Growth is anchored in TLANDO licensing, including an $11.0 million Verity deal and UAE approval for TESTYRA, alongside a CNS pipeline where lead PPD candidate LPCN 1154 recently failed to meet its Phase 3 primary endpoint, prompting further analyses, a new trial, and an upcoming FDA meeting.
Lipocine Inc. expanded its Board of Directors to five members and appointed Michael J. Grissinger as a director, effective August 3, 2026. The board determined that he qualifies as an independent director under Nasdaq listing standards.
Upon joining, Grissinger receives an initial stock option grant to purchase 2,000 shares of Lipocine common stock and an annual non-employee director cash retainer of $55,000. He brings extensive business development and M&A experience from senior roles at Johnson & Johnson and prior work at Ciba-Geigy, and currently serves on several public biotech boards.
Lipocine describes a pipeline of orally delivered drug candidates, including programs in postpartum depression, major depressive disorder, epilepsy, essential tremor, obesity management, liver cirrhosis, and preterm birth, alongside its FDA-approved oral testosterone product TLANDO. The company furnished a press release detailing the appointment and its strategic rationale.
Lipocine Inc. director and CEO Mahesh V. Patel received a new stock option grant as part of his compensation. He was awarded options to acquire 52,781 shares of Lipocine common stock at an exercise price of $2.49 per share, bringing his total stock option holdings reported in this filing to 227,214 options.
The grant is subject to vesting: one-third of the options will vest on June 29, 2027, and the remaining two-thirds will vest monthly on a prorated basis over the following two years. This structure is designed to tie his equity compensation to continued service and long-term performance.
Lipocine Inc. filed a report describing a virtual key opinion leader event held on June 12, 2026. The event focused on unmet medical needs in postpartum depression and reviewed the clinical profile of the company’s investigational product candidate LPCN 1154.
The related slide presentation was furnished as Exhibit 99.1 and is incorporated by reference. Lipocine notes that a link to the presentation is available on its corporate website, giving investors and clinicians access to the detailed discussion from the event.
Lipocine Inc. held its annual shareholder meeting on June 3, 2026 and approved the Sixth Amended and Restated 2014 Stock and Incentive Plan. The amendment raises individual award limits from 25,000 to 100,000 shares and increases available common stock awards by 400,000 shares, so the plan now authorizes up to 1,000,000 shares in total. Shareholders re-elected four directors and ratified Tanner LLC as independent registered public accountants for the fiscal year ending December 31, 2026. They also approved a say‑on‑pay advisory vote on executive compensation, the amended stock and incentive plan, and an adjournment proposal to continue soliciting votes on these matters.
Higuchi John W. reported acquisition or exercise transactions in this Form 4 filing.
Lipocine Inc. director John W. Higuchi received a grant of derivative securities giving him the right to buy 1,764 shares of common stock at $2.19 per share. These rights vest 100% one year from the grant date and expire on June 3, 2036. Following this award, Higuchi holds rights to purchase a total of 13,290 shares of common stock.
Lipocine Inc. director Jene Jill M. received a grant of stock options covering 1,764 shares of common stock at an exercise price of $2.19 per share. These options vest 100% one year from the grant date and expire on June 3, 2036. Following this grant, the director holds a total of 8,938 derivative securities directly.
Ono Richard Dana reported acquisition or exercise transactions in this Form 4 filing.
Lipocine Inc. director Richard Dana Ono received an equity award in the form of derivative rights to buy 1,764 shares of Common Stock at $2.19 per share. This grant is a compensation-related award, not an open-market purchase or sale. The rights vest 100% one year from the grant date and are exercisable until June 3, 2036. After this award, Ono holds derivative rights covering a total of 13,290 shares of Lipocine common stock directly.
Lipocine Inc. filed an 8-K announcing a virtual Key Opinion Leader event focused on postpartum depression and its investigational oral therapy LPCN 1154 (BRLIZIO™). The webcast will be held on Friday, June 12, 2026 at 11:00 AM Eastern Time and feature leading psychiatrists discussing unmet needs in postpartum depression and Phase 3 topline results for LPCN 1154.
LPCN 1154 is an oral formulation of brexanolone designed to deliver bioequivalent exposure to intravenous ZULRESSO® over 48 hours at home, without medical monitoring. In a Phase 3 trial, a subgroup analysis excluding an epidemiologic outlier site showed clinically meaningful, statistically significant efficacy with 100% dosing-period completion and no treatment-related serious adverse events. LPCN 1154 is not yet FDA approved; BRLIZIO™ is a conditionally approved brand name.
Lipocine Inc. filed a current report describing a scientific presentation rather than a financial event. On May 26, 2026, the company presented Phase 3 clinical data for LPCN 1154, an oral brexanolone candidate for treating postpartum depression, at the American Society of Clinical Psychopharmacology Annual Meeting in Miami Beach.
The presentation and a related scientific poster, which summarize results from a placebo-controlled Phase 3 clinical trial in postpartum depression, are included as Exhibits 99.1 and 99.2 to the report and incorporated by reference for full clinical details.